Published in Vaccine on April 19, 2015
Building the case for wider use of typhoid vaccines. Vaccine (2015) 0.78
Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis. Clin Vaccine Immunol (2016) 0.77
Role of T3SS-1 SipD Protein in Protecting Mice against Non-typhoidal Salmonella Typhimurium. PLoS Negl Trop Dis (2016) 0.75
TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Regulates CXCR5+ T helper Cells in the Intestine. J Clin Cell Immunol (2016) 0.75
Animal Models for Salmonellosis: Applications in Vaccine Research. Clin Vaccine Immunol (2016) 0.75
Salmonella Serogroup C: Current Status of Vaccines and Why They Are Needed. Clin Vaccine Immunol (2016) 0.75
Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. Ecosal Plus (2016) 0.75
Salmonella co-opts host cell chaperone-mediated autophagy for intracellular growth. J Biol Chem (2016) 0.75
Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells. PLoS Negl Trop Dis (2017) 0.75
Two Novel Salmonella Bivalent Vaccines Confer Dual Protection against Two Salmonella Serovars in Mice. Front Cell Infect Microbiol (2017) 0.75
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A (2000) 96.90
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (1981) 19.90
A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc Natl Acad Sci U S A (1989) 9.79
A Salmonella locus that controls resistance to microbicidal proteins from phagocytic cells. Science (1989) 7.58
Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium. Proc Natl Acad Sci U S A (1996) 6.42
Identification of a pathogenicity island required for Salmonella survival in host cells. Proc Natl Acad Sci U S A (1996) 5.36
Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival. Mol Microbiol (1998) 5.25
Genes encoding putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2 are required for bacterial virulence and proliferation in macrophages. Mol Microbiol (1998) 5.07
Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol (1978) 4.91
Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc Natl Acad Sci U S A (1989) 4.62
Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis (1975) 4.51
Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun (1987) 4.28
Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet (2012) 4.02
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
An essential role for DNA adenine methylation in bacterial virulence. Science (1999) 3.80
The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol (1991) 3.52
Salmonella typhimurium loci involved in survival within macrophages. Infect Immun (1994) 3.32
The HtrA family of serine proteases. Mol Microbiol (1997) 3.14
Gene replacement without selection: regulated suppression of amber mutations in Escherichia coli. Gene (2003) 2.73
phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis (1996) 2.58
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Roles of DNA adenine methylation in regulating bacterial gene expression and virulence. Infect Immun (2001) 2.42
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: studies with an aromatic-dependent live S. typhimurium strain as a vaccine. Infect Immun (1985) 2.40
Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog (1989) 2.32
Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease, and treatment. Clin Microbiol Rev (2004) 2.26
Identification of a pathogenicity island required for Salmonella enteropathogenicity. Mol Microbiol (1998) 2.23
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 2.17
Signatures of adaptation in human invasive Salmonella Typhimurium ST313 populations from sub-Saharan Africa. PLoS Negl Trop Dis (2015) 2.16
Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb Pathog (1992) 2.04
A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun (1988) 1.86
DNA adenine methylase mutants of Salmonella typhimurium show defects in protein secretion, cell invasion, and M cell cytotoxicity. Proc Natl Acad Sci U S A (1999) 1.86
The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis (2005) 1.81
Further characterization of the PhoP regulon: identification of new PhoP-activated virulence loci. Infect Immun (1994) 1.80
Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon. Mol Microbiol (1996) 1.78
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine (1992) 1.69
Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev (2006) 1.65
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 1.63
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Salmonella DNA adenine methylase mutants confer cross-protective immunity. Infect Immun (2001) 1.59
SseBCD proteins are secreted by the type III secretion system of Salmonella pathogenicity island 2 and function as a translocon. J Bacteriol (2001) 1.58
Vaccination against typhoid fever: present status. Bull World Health Organ (1994) 1.52
Turnover of FlhD and FlhC, master regulator proteins for Salmonella flagellum biogenesis, by the ATP-dependent ClpXP protease. Mol Microbiol (2003) 1.49
Progress in vaccines against typhoid fever. Rev Infect Dis (1989) 1.49
Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice. J Immunol (1984) 1.48
Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol (1996) 1.47
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun (2002) 1.47
ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem (2004) 1.41
Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet (1990) 1.40
Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest (1992) 1.39
Immunity conferred by Aro- Salmonella live vaccines. Microb Pathog (1991) 1.38
Test of the virulence and live-vaccine efficacy of auxotrophic and galE derivatives of Salmonella choleraesuis. Infect Immun (1987) 1.35
Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect Immun (1992) 1.33
The ClpXP ATP-dependent protease regulates flagellum synthesis in Salmonella enterica serovar typhimurium. J Bacteriol (2002) 1.32
In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun (2000) 1.32
Salmonella DNA adenine methylase mutants elicit protective immune responses to homologous and heterologous serovars in chickens. Infect Immun (2001) 1.31
Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar typhimurium. Infect Immun (2011) 1.30
Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun (2011) 1.29
Characterization and immunogenicity of Salmonella typhimurium SL1344 and UK-1 delta crp and delta cdt deletion mutants. Infect Immun (1997) 1.29
Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis (2007) 1.28
Correlates of protection induced by live Aro- Salmonella typhimurium vaccines in the murine typhoid model. Immunology (1997) 1.24
Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun (2011) 1.23
Control of colonization by virulent Salmonella typhimurium by oral immunization of chickens with avirulent delta cya delta crp S. typhimurium. Res Microbiol (1991) 1.19
Vaccines against invasive Salmonella disease: current status and future directions. Hum Vaccin Immunother (2014) 1.19
CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis (2007) 1.14
Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect Immun (1999) 1.13
Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol (2012) 1.12
Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development. Expert Rev Vaccines (2013) 1.10
Oral immunization: an update. Curr Opin Gastroenterol (2008) 1.06
Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis (2004) 1.04
Effect of vaccination of hens with an avirulent strain of Salmonella typhimurium on immunity of progeny challenged with wild-Type Salmonella strains. Infect Immun (1996) 1.03
Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs. Infect Immun (1999) 1.03
Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun (1993) 1.03
The PhoP virulence regulon and live oral Salmonella vaccines. Vaccine (1993) 1.03
Safety, efficacy, and duration of immunity induced in swine by use of an avirulent live Salmonella choleraesuis-containing vaccine. Am J Vet Res (1995) 1.01
Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS One (2013) 1.00
Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine (2005) 0.99
Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun (2000) 0.99
Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin Diagn Lab Immunol (2005) 0.96
In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine (2010) 0.94
The delicate balance in genetically engineering live vaccines. Vaccine (2013) 0.92
Biological and virulence characteristics of Salmonella enterica serovar Typhimurium following deletion of glucose-inhibited division (gidA) gene. Microb Pathog (2011) 0.92
A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One (2010) 0.91
Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years. Int J Med Microbiol (2009) 0.90
Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. J Infect Dis (1992) 0.90
Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol (2014) 0.89
Comparison of the abilities of Salmonella typhimurium rpoS, aroA and rpoS aroA strains to elicit humoral immune responses in BALB/c mice and to cause lethal infection in athymic BALB/c mice. Microb Pathog (1999) 0.89
Novel attenuated Salmonella enterica serovar Choleraesuis strains as live vaccine candidates generated by signature-tagged mutagenesis. Infect Immun (2005) 0.87
Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella? Vaccine (2012) 0.85
Non-typhoidal Salmonella Typhimurium ST313 isolates that cause bacteremia in humans stimulate less inflammasome activation than ST19 isolates associated with gastroenteritis. Pathog Dis (2014) 0.85
M-01ZH09, an oral live attenuated Salmonella enterica serovar Typhi vaccine for the prevention of typhoid fever. Curr Opin Mol Ther (2009) 0.85
The effect of exposure to a delta cya/delta crp mutant of Salmonella typhimurium on the subsequent colonization of swine by the wild-type parent strain. Vet Microbiol (1992) 0.84
Invasive Salmonella Typhimurium ST313 with naturally attenuated flagellin elicits reduced inflammation and replicates within macrophages. PLoS Negl Trop Dis (2015) 0.84
Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates. Vaccine (2013) 0.84
Enterobacterial common antigen mutants of Salmonella enterica serovar Typhimurium establish a persistent infection and provide protection against subsequent lethal challenge. Infect Immun (2011) 0.83
Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice. PLoS One (2012) 0.82
Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine (2010) 0.82